When: Close at $250-252 (50 SMA zone) with confirmed bullish reversal (hammer candle OR volume capitulation + higher low within 3 sessions) AND MACD histogram re-expanding

Then: Deploy 2-3% tranche

HOLD with hardened risk management: do not add at 256 or 250 until confirmed breakout above 267 on expanding volume or flush to 200 SMA near 225 with stabilization; tighten trim trigger to close below 251 on volume (50 SMA at 251.20); accept potentially missing upside rather than adding into a deteriorating setup.

• PEG of 0.42 is built on forward EPS of 16.28, requiring normalization assumptions that ignore TTM P/E of 72.2 (GAAP reality) and negative book value with 70B in debt
• Price sequence from 266.97 to 256.42 shows clean break below prior swing low at 258.15, indicating consolidation is not holding its own range
• MACD line at 3.50 versus peak of 10.45 two months ago is a 66 percent collapse in momentum breadth; negative histogram flip is regime change in market internals, not rounding error
• EMA filing is regulatory submission, not approval—pipelines routinely disappoint on timelines and outcomes
• Macro regime: 72 percent probability of Fed hike in 2026, 89 percent probability of no cuts; beta of 0.28 protects against volatility, not multiple compression or yield-driven repricing
• Asymmetry fails: from 256.42, 13x multiple on EPS 16.28 yields ~212 (17% downside) versus 280-290 (9-13% upside); roughly symmetric before weighting pipeline, debt, and macro risks
• Adding on flush to 250 with same 244 stop increases basis without changing dollar risk—adding size into deteriorating setup is not disciplined risk management

→ vs aggressive: PEG of 0.42 is not a value signal but a flag that GAAP story is being papered over with normalized forward EPS assumptions while TTM P/E of 72.2 and 70B debt are ignored

→ vs aggressive: Lower highs are not pattern-matching bias—they are price action the aggressive case requires ignoring to substitute hope for analysis

→ vs aggressive: MACD at minus 0.01 is not basis point noise; the histogram flipping negative is direction of momentum failing to confirm price for the first time since the rally began—a regime change

→ vs aggressive: Skyrizi EMA filing is a regulatory submission, not a commercial catalyst—the aggressive analyst is treating an undelivered regulatory event as done deal

→ vs aggressive: Beta of 0.28 does not protect against multiple compression or secular yield-driven repricing; healthcare multiples have moved with rates through every cycle of the past decade

→ vs aggressive: Asymmetry argument breaks down under honest scenario weighting: 17% downside versus 12-16% upside is roughly symmetric before weighting in pipeline, debt, and macro risks

→ vs aggressive: Adding on flush to 250 with same 244 stop does not change dollar risk per share but does change the basis from which the position is evaluated—adding capital at a moment when technicals confirm the bear case

HOLD with three modifications: (1) tactical starter add at 50 SMA zone of 250 to 252 on confirmed bullish reversal price action, sized to no more than 25 percent of current position; (2) trim trigger tightened to close below 248 on volume with hard stop at 244; (3) time-based reassessment: if no reclaim of 10 EMA with momentum confirmation or clean flush to 50 SMA with reversal action within 10 trading sessions, reduce position size by one-third.

• The aggressive analyst overreaches by dismissing MACD histogram signal and overstating EMA filing as commercial catalyst
• The conservative analyst overreaches by inverting the analytical question on lower highs and being too rigid on support levels
• HOLD is the right baseline because the stock is a high-quality defensive in a healthy long-term uptrend digesting a 35 percent rally through a normal pullback
• 50 SMA zone of 250 to 252 is real support but requires confirmed bullish reversal conditions for add
• Trim trigger at 248 is more appropriate than 251.20 to avoid trimming at the same level used for re-entry
• Hawkish Fed regime compresses multiples but creates flight-to-quality bid into defensive names
• ABBV has beta of 0.28, dividend aristocrat status, and predictable cash flows
• Bear case requires simultaneous multiple compression from 15.75x to 13x while holding forward EPS at 16.28, a non-trivial two-step
• Position sizing should account for modest multiple compression, not expansion or collapse
• Diversification alternatives mentioned: JNJ offers more balance sheet diversification, LLY offers more growth
• 244 is the hard stop level below the 50 SMA support
• A close at or below 251.20 with bullish reversal confirmation (hammer candle or volume capitulation with higher low within three sessions) are the specific conditions for tactical add

→ vs aggressive: Dismissal of MACD histogram as 'one basis point' is rhetorical sleight of hand; the directional change from positive to negative territory is a regime-level signal when momentum had been confirming price for two months straight

→ vs aggressive: EMA filing is not a commercial catalyst in any near-term sense; review periods run many months, label expansions are not guaranteed, and commercial lift depends on payor access, physician adoption, and competitive response

→ vs aggressive: Macro characterization of 'supportive' without qualification overstates the case; a hawkish Fed with 72 percent hike probability and 89 percent no-cut probability compresses multiples across the board

→ vs aggressive: Bear case requiring both multiple compression from 15.75x to 13x and forward EPS holding at 16.28 is a non-trivial two-step that is possible but not the base case

→ vs conservative: Framing of lower highs as 'real price action' is a complete inversion of the analytical question; lower highs within a stock up 35 percent in 13 months at a fresh swing high are not the same signal as lower highs after breakdown from a long-term top

→ vs conservative: Refusal to add at the 50 SMA zone of 250 to 252 is inflexibility, not discipline; that level is the single strongest defined support in the entire structure above the 200 SMA

→ vs conservative: Suggestion to wait for a flush to 225 before adding is anchoring on a level that may simply never be tested if macro stays supportive and Skyrizi/Rinvoq keep delivering